

Theme	Topics	Subtopics
Basic and Translational Science	Development of New Models and Analysis Methods	<ul style="list-style-type: none"> <li>• <math>\alpha</math>-synuclein</li> <li>• Amyloid/Abeta</li> <li>• Behavioral models</li> <li>• Inflammation</li> <li>• Novel assays and technologies</li> <li>• Screening studies/platforms</li> <li>• Seeding and spreading of proteinopathies</li> <li>• Tau</li> <li>• TDP-43</li> <li>• Validation of pre-clinical methods</li> </ul>
	Genetics	<ul style="list-style-type: none"> <li>• Blood-borne markers of CNS disease</li> <li>• Endophenotypes</li> <li>• Epigenetics</li> <li>• Genetic factors of Alzheimer's disease</li> <li>• Genetic factors of non-Alzheimer's tauopathies</li> <li>• Genetics of cognitive aging</li> </ul>
	Molecular and cell biology	<ul style="list-style-type: none"> <li>• <math>\alpha</math>-synuclein</li> <li>• <math>\beta</math>-amyloidosis</li> <li>• APP/Abeta/Amyloid</li> <li>• Axonal transport</li> <li>• Calcium homeostasis</li> <li>• Cell cycle disruption</li> <li>• Endosomal-lysosomal dysfunction</li> <li>• Enzyme activities</li> <li>• Inflammation</li> <li>• Mitochondrial function/energetics</li> <li>• Neurodegeneration and Neuroprotection</li> </ul>

		<ul style="list-style-type: none"> <li>• Neurofibrillary degeneration</li> <li>• Neuronal cell death mechanisms (i.e. apoptosis)</li> <li>• Neurotrophin mechanisms</li> <li>• Others</li> <li>• Oxidative stress</li> <li>• Presenilins</li> <li>• Protein clearance/recycling</li> <li>• Receptors</li> <li>• Signal transduction</li> <li>• Stem Cells, IPS cells</li> <li>• Synaptic disruption</li> <li>• Tau</li> <li>• TDP-43</li> <li>• Vascular factors</li> </ul>
	Protein-Protein interactions	<ul style="list-style-type: none"> <li>• <i>No subtopics</i></li> </ul>
Theme	Topics	Subtopics
Diagnosis and Prognosis	Biomarkers (non-neuroimaging)	<ul style="list-style-type: none"> <li>• Differential diagnosis</li> <li>• Longitudinal change over time</li> <li>• Method development and/or quality control</li> <li>• Multi-modal comparisons</li> <li>• Novel biomarkers</li> <li>• Plasma/serum/urine biomarkers</li> <li>• Prognostic utility</li> <li>• Use in clinical trial design and evaluation</li> </ul>

	Clinical (neuropsychiatry and behavioral neurology)	<ul style="list-style-type: none"> <li>• Assessment/measurement of neuropsychiatric/behavioral and psychological symptoms</li> <li>• Behavioral neurology</li> <li>• Cross-cultural issues</li> <li>• Dementia</li> <li>• Mild cognitive impairment/early symptomatic disease</li> <li>• Neuropsychiatry</li> <li>• Non-pharmacologic interventions</li> <li>• Normal cognitive aging, including oldest old</li> <li>• Presymptomatic disease/prodromal disease/prodromal states</li> <li>• Symptom clusters and syndromes</li> <li>• Treatment development and clinical trials</li> </ul>
	Neuroimaging	<ul style="list-style-type: none"> <li>• Animal imaging</li> <li>• Differential diagnosis</li> <li>• Evaluating treatments</li> <li>• Imaging and genetics</li> <li>• Multi-modal comparisons</li> <li>• New imaging methods</li> <li>• Normal brain aging</li> <li>• Optimal neuroimaging measures for early detection</li> <li>• Optimal neuroimaging measures for tracking disease progression</li> </ul>
	Neuropathology	<ul style="list-style-type: none"> <li>• Alpha-synuclein</li> <li>• Amyloid</li> <li>• Etiopathogenesis--links to brain disease</li> </ul>

		<ul style="list-style-type: none"> <li>• Novel methods</li> <li>• Other</li> <li>• Proteinopathies</li> <li>• Selective vulnerability</li> <li>• Tau</li> <li>• Topography of pathology</li> <li>• Vascular</li> </ul>
	Neuropsychology	<ul style="list-style-type: none"> <li>• Computerized neuropsychological assessment</li> <li>• Early detection of cognitive decline with neuropsychological tests</li> <li>• Multicultural issues in assessment of dementia</li> <li>• Neuropsychological correlates of physiologic markers of cognitive decline/dementia</li> <li>• Neuropsychological profiles of dementia: Valid biomarkers?</li> <li>• Normal cognitive aging</li> </ul>
Theme	Topics	Subtopics
Public Health and Psychosocial	Dementia Care Practice	<ul style="list-style-type: none"> <li>• Innovative programs and practices</li> <li>• Leadership and staff development</li> <li>• Policy and systems change</li> <li>• Program evaluation and care interventions</li> </ul>
	Epidemiology	<ul style="list-style-type: none"> <li>• Epidemiology of MCI and dementia</li> <li>• Epidemiology of risk factors of Alzheimer's or all-cause dementia</li> <li>• Epidemiology of risk factors of vascular dementia or other dementias</li> </ul>

		<ul style="list-style-type: none"> <li>• Prevention (primary or secondary)</li> </ul>
	Health Economics and Policy	<ul style="list-style-type: none"> <li>• Cost of care</li> <li>• Policy and plans</li> <li>• Services</li> </ul>
	Psychosocial and Environmental	<ul style="list-style-type: none"> <li>• Assessment and care planning</li> <li>• Behavioral interventions</li> <li>• Environmental design and technology</li> <li>• Family/lay caregiving</li> <li>• Instrument development, program evaluation and translation</li> <li>• Living with dementia and quality of life</li> <li>• Long-term and community care</li> <li>• Prevention (primary or secondary)</li> <li>• Therapeutic strategies and interventions</li> </ul>
Theme	Topics	Subtopics
Therapeutics	Clinical	<ul style="list-style-type: none"> <li>• Ethical issues</li> <li>• Human trials: Cognitive enhancement</li> <li>• Human trials: Nutraceuticals and non-pharmacological interventions</li> <li>• Human trials: Other behavioral symptoms</li> <li>• Human trials: Anti-amyloid</li> <li>• Human trials: Anti-tau</li> <li>• Human trials: Inflammation</li> <li>• Human trials: Other</li> <li>• Novel outcomes measures</li> <li>• Trial design</li> </ul>

	Preclinical	<ul style="list-style-type: none"> <li>• Lead optimization studies</li> <li>• Natural products and nutraceuticals</li> <li>• Non-pharmacological interventions</li> <li>• Novel screening strategies</li> <li>• Target identification and validation studies: Amyloid</li> <li>• Target identification and validation studies: Cognitive enhancement and other behavioral symptoms</li> <li>• Target identification and validation studies: Inflammation and innate immunity</li> <li>• Target identification and validation studies: Mitochondria and neuroprotection</li> <li>• Target identification and validation studies: Other</li> <li>• Target identification and validation studies: Proteostasis</li> <li>• Target identification and validation studies: Tau</li> </ul>
--	-------------	---